[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-prognosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-prognosis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100571781","diagnosis-of-atrial-fibrillation-in-postoperative-thoracic-surgery-using-a-smartwatch-100571781",false,"NCT06724718","Diagnosis of Atrial Fibrillation in Postoperative Thoracic Surgery Using a Smartwatch","THO-FA-WATCH","Inclusion Criteria:\n\n* Adults (\\>18 years old).\n* Patients undergoing major thoracic surgery with one-lung ventilation within the past 48 hours.\n* Scheduled pneumonectomy or lobectomy.\n* Admission to a conventional surgical unit postoperatively.\n* Ability to perform single-lead ECG using a smartwatch.\n* Coverage under a social security system.\n* Signed informed consent\n\nExclusion Criteria:\n\n* History of atrial fibrillation.\n* Requirement for telemetry for AV block or tachyarrhythmias (\\>140 bpm).\n* Dependency on a pacemaker.\n* Participation in another interventional clinical trial affecting POAF incidence.\n* Mediastinal, pleural, or chest wall surgery.\n* Reoperations or surgeries performed more than 48 hours prior.\n* Pregnant women.\n* Patients under guardians or similar legal protection.","ALL","18 Years",{"count":19,"type":20},302,"ESTIMATED","INTERVENTIONAL",[23],"NA","Postoperative atrial fibrillation (POAF) occurs in approximately 20% of patients following thoracic surgery. Early diagnosis is essential to prevent complications such as heart failure, stroke, myocardial infarction, and increased mortality. Smartwatches equipped with single-lead ECG capabilities and algorithms to detect asymptomatic atrial fibrillation (AF) offer a potential solution. This study aims to evaluate the effectiveness of smartwatches in detecting POAF compared to standard care.",[26,27,28,29,30,31,32],"Postoperative Atrial Fibrillation","Thoracic Surgery","Smartwatches","Rhythm Monitoring","Cardiovascular Prognosis","Asymptomatic Atrial Fibrillation","Randomized Trial",[34,35,36,37,38,39,40],"Postoperative atrial fibrillation","thoracic surgery","smartwatches","rhythm monitoring","cardiovascular prognosis","asymptomatic atrial fibrillation","randomized trial","RECRUITING","2025-06-11",{"date":44,"type":45},"2025-06-12","ACTUAL",{"date":47,"type":45},"2025-06-01",{"date":49,"type":20},"2027-12",{"name":51,"class":52},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":53},"100489935","prognostic-role-of-the-uremic-toxin-indoxyl-sulfate-on-vascular-and-cardiac-functions-during-acute-kidney-injury-100489935","NCT05659589","Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury","VASC-AKI","Inclusion Criteria:\n\n* Age over 18 years old.\n* Patients hospitalized in conventional hospital departments and in intensive care units of nephrology.\n* Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis.\n* AKI from functional or organic aetiology\n\nExclusion Criteria:\n\n* Patients with severe CKD (GFR\\\u003C45ml\u002Fmin\u002F1.73 m2) or with kidney transplants.\n* Patients with AKI from septic or obstructive aetiology.\n* Patients with AKI from toxic aetiology whose toxic would be also responsable of cardia toxicity.\n* Patients with sepsis or blood inflammation.\n* Patients with severe chronic cardia dysfunction.\n* Patients with arrhythmia or complete heart block.\n* Patients with peripheral artery occlusive disease.\n* Pregnancy.\n* Patients on palliative care.",{"count":62,"type":20},105,[23],"Acute kidney injury (AKI) is a frequent disease in conventional hospital departments and in intensive care units. It's associated with a high risk to develop chronic kidney disease (CKD), even after a single small AKI episode. It's also associated with an important morbi-mortality, particularly cardiovascular (CV). Some studies have already showed a link between AKI and CV risk but pathologic mechanisms implicated are still unknown. In AKI and CKD, numerous substances, called uremic toxins (UT) are accumulating in blood. In CKD, those toxins, and particularly Indoxyl sulfate (IS), are known to have cardiac and vascular deleterious consequences. However, in AKI, whether acute accumulation of UT may trigger CV complications is unknown.\n\nThe purpose of this study is that during AKI, a high UT concentration, in particular IS, would be associated with early vascular and cardiac dysfunctions that can be characterized by the persistence of an accelerated pulse wave velocity (PWV). The main objective is to evaluate the correlation between UT concentrations (especially IS) and arterial stiffness (PWV measurement) at three months of an AKI episode in conventional hospital departments and in the intensive care unit of nephrology.",[66,67,68,69,30],"Acute Kidney Injury","Uremic; Toxemia","Vascular Dysfunction","Cardiac Dysfunction",[66,67,71,72,38],"vascular dysfunction","cardiac dysfunction","2025-05-22",{"date":75,"type":45},"2025-05-28",{"date":77,"type":45},"2022-12-13",{"date":79,"type":20},"2026-06",{"name":51,"class":52},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":53},"100323559","cardiovascular-outcome-of-cancer-patients-the-gmedico-cohort-100323559","NCT03492528","Cardiovascular Outcome of Cancer Patients: The \"GMEDICO Cohort\"","GMEDICO","Inclusion Criteria:\n\n* All adults referred for specialist cardio-oncology consultations before the initiation of a cancer treatment according to pre-established indications will be eligible.\n\nExclusion Criteria:\n\n* Failure to provide information that makes it impossible to complete a consultation form or refuse to sign the consent.\n* Minor or major patient under guardianship\n* Pregnant or breastfeeding woman",{"count":89,"type":20},530,[23],"The Mediterranean Group of Cardio-Oncology (GMEDICO) brings together French cardiologists and oncologists who have developed a protocol for the monitoring and cardio-oncological management of patients treated for cancer.\n\nThis unique organization makes it possible to envisage the creation of a large cohort from which the incidence and predictive factors of cardiovascular toxicity can be determined.\n\nPrimary objective: to determine the cardiovascular prognosis of patients treated for cancer and followed up in cardio-oncology.\n\nSecondary objectives\n\n* To determine the clinical, biological and imaging factors associated with cardiovascular events under cancer treatment, in order to define a risk score including clinical, biological (biomarker) and imaging data.\n* To create a biological source for testing other biomarkers and conducting genome-wide association studies and genetic factors associated with cardiovascular events under cancer treatment.",[30],"2022-09-19",{"date":95,"type":45},"2022-09-21",{"date":97,"type":45},"2019-07-05",{"date":99,"type":20},"2027-10",{"name":101,"class":52},"Assistance Publique Hopitaux De Marseille"]